BrightGene Bio-Medical Technology Co Ltd
SSE:688166
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.3
39.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BrightGene Bio-Medical Technology Co Ltd
Wall Street
Price Targets
Price Targets Summary
BrightGene Bio-Medical Technology Co Ltd
According to Wall Street analysts, the average 1-year price target for
BrightGene Bio-Medical Technology Co Ltd
is 45.09 CNY
with a low forecast of 44.65 CNY and a high forecast of 46.42 CNY.
Revenue
Forecast
Revenue Estimate
BrightGene Bio-Medical Technology Co Ltd
For the last 6 years the
compound annual growth rate for
BrightGene Bio-Medical Technology Co Ltd's revenue is
24%.
The projected
CAGR
for the next 3 years is
14%.
Operating Income
Forecast
Operating Income Estimate
BrightGene Bio-Medical Technology Co Ltd
For the last 6 years the
compound annual growth rate for
BrightGene Bio-Medical Technology Co Ltd's operating income is
27%.
The projected
CAGR
for the next 3 years is
21%.
Net Income
Forecast
Net Income Estimate
BrightGene Bio-Medical Technology Co Ltd
For the last 6 years the
compound annual growth rate for
BrightGene Bio-Medical Technology Co Ltd's net income is
28%.
The projected
CAGR
for the next 3 years is
16%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BrightGene Bio-Medical Technology Co Ltd's stock price target?
Price Target
45.09
CNY
According to Wall Street analysts, the average 1-year price target for
BrightGene Bio-Medical Technology Co Ltd
is 45.09 CNY
with a low forecast of 44.65 CNY and a high forecast of 46.42 CNY.
What is BrightGene Bio-Medical Technology Co Ltd's Revenue forecast?
Projected CAGR
14%
For the last 6 years the
compound annual growth rate for
BrightGene Bio-Medical Technology Co Ltd's revenue is
24%.
The projected
CAGR
for the next 3 years is
14%.
What is BrightGene Bio-Medical Technology Co Ltd's Operating Income forecast?
Projected CAGR
21%
For the last 6 years the
compound annual growth rate for
BrightGene Bio-Medical Technology Co Ltd's operating income is
27%.
The projected
CAGR
for the next 3 years is
21%.
What is BrightGene Bio-Medical Technology Co Ltd's Net Income forecast?
Projected CAGR
16%
For the last 6 years the
compound annual growth rate for
BrightGene Bio-Medical Technology Co Ltd's net income is
28%.
The projected
CAGR
for the next 3 years is
16%.
You don't have any saved screeners yet
